New Product Release: Endo S2

Endo-S2 is an endo-β-N-acetylglucosaminidase derived from Streptococcus pyogenes that cleaves the glycosidic bond between the two innermost N-acetylglucosamine (GlcNAc) residues in the N-linked glycans of glycoproteins. It is applicable to IgG from humans, as well as IgG antibodies from mice, rats, monkeys, goats, sheep, cows, and horses. Endo-S2 exhibits broad substrate specificity, effectively acting on the three major types of N-glycans: high-mannose, hybrid, and complex. Additionally, research has shown that Endo-S2 demonstrates significant activity in transglycosylation reactions.

Figure 1. Schematic Illustration of Endo-S2 Hydrolysis of Rituximab and Transglycosylation

Endo-S2 can recognize both core-fucosylated and non-fucosylated GlcNAc molecules in the Fc domain, utilizing them as acceptors for transglycosylation. Studies have demonstrated that Endo-S2 can efficiently remodel the glycosylation of rituximab and trastuzumab (Herceptin), producing homogeneous glycoforms without side reactions (Figure 2). As a result, it is widely applicable for structural and functional studies of antibodies with uniform glycoforms, as well as for the development of more effective antibody-based therapies.

Figure 2. Specificity of Endo-S2 Toward Monoclonal Antibodies with Different Glycans

Product Information

Purity: >95%

Activity: 200 U/μl

Tag: His-Tag

Storage Conditions: -25 to -15 °C for 24 months

Figure 3. Results of Endo-S2 Treatment on Human IgG

M marker
Lan1  human IgG 5μg
Lan2  human IgG 5μg+20 U Endo S2
Lan3  human IgG 5μg+10 U Endo S2
Lan4  human IgG 5μg+5 U Endo S2
Lan5  human IgG 5μg+2.5 U Endo S2
Lan6  human IgG 5μg+1 U Endo S2
Lan7  human IgG 5μg+0.5 U Endo S2

Click on the product code below to access the official product page for more details.